A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

Bone

Volumn 24, Issue 5, 1999, Pages 437-449

  Missbach, M ^a   Jeschke, M ^a   Feyen, J ^a   Muller K ^a   Glatt, M ^a   Green, J ^a   Susa M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fak; IL 1; Osteoblast; Osteoporosis; Protein kinase; Signal transduction

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CGP 77675; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FOCAL ADHESION KINASE; INTERLEUKIN 1BETA; PARATHYROID HORMONE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BONE CELL; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME SPECIFICITY; FEMALE; GENE OVEREXPRESSION; HYPERCALCEMIA; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

3T3 CELLS; ANIMALS; BONE DISEASES, METABOLIC; BONE RESORPTION; CELL ADHESION MOLECULES; CELL SURVIVAL; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MALE; MICE; ONCOGENE PROTEIN PP60(V-SRC); OSTEOBLASTS; OVARIECTOMY; PAXILLIN; PHOSPHOPROTEINS; PHOSPHORYLATION; PREGNANCY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032904762     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00020-4     Document Type: Article

References (59)

1. Abu-Amer Y., Ross F.P., Schlesinger P., Tondravi M.M., Teitelbaum S.L. Substrate recognition by osteoclast precursors induces c-src/microtubule association. J Cell Biol. 137:1997;247-258.
2. Baron R., Ravesloot J.-H., Neff L., Chakraborty M., Chatterjee D., Lomri A., Horne W. Cellular and molecular biology of the osteoclast. Noda M. Cellular and molecular biology of bone. 1993;445-495 Academic Press, San Diego, CA.
3. c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 90:1992;1622-1627.
4. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Regenass U., Lydon N.B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 92:1995;2558-2562.
5. Calalb M.B., Zhang X., Polte T.R., Hanks S.K. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun. 228:1996;662-668.
6. Canalis E., Rydziel S. Platelet-derived growth factor and the skeleton. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of bone biology. 1996;619-626 Academic Press, San Diego, CA.
7. Dahring T.K., Lu G.H., Hamby J.M., Batley B.L., Kraker A.J., Panek R.L. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 281:1997;1446-1456.
8. Dave C.G., Shah P.R., Upadhyay S.P., Ghandi T.P., Patel R.B. Synthesis and biological activity of pyrrolo[2,3-d]pyrimidines. Indian J Chem. 27B:1988;778-780.
9. Feyen J.H.M., Cardinaux F., Gamse R., Bruns C., Azria M., Trechsel U. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo. Biochem Biophys Res Commun. 187:1992;8-13.
10. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 258:1992;1903-1910.
11. Gunness-Hey M., Hock J.M. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Rel Res. 5:1984;177-181.
12. Hahn M., Vogel M., Pompesius-Kempa M., Delling G. Trabecular bone pattern factor - a new parameter for simple quantification of bone microarchitecture. Bone. 13:1992;327-330.
13. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Conelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J Biol Chem. 271:1996;695-701.
14. c-src in association with intracellular membranes. J Cell Biol. 119:1992;1003-1013.
15. Hruska K.A., Rolnick F., Huskey M., Alvarez U., Cheresh D. Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology. 136:1995;2984-2992.
16. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
17. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 3:1997;1285-1289.
18. Izbicka E., Niewolna M., Yoneda T., Lowe C., Boyce B., Mundy G. pp60 c-src expression and activity in MG-63 osteoblastic cells modulated by PTH but not required for PTH-mediated adenylate cyclase response. J Bone Miner Res. 9:1994;127-132.
19. Jamall I.S., Finelli V.N., Que Hee S.S. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 112:1981;70-75.
20. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15:1991;175-191.
21. Kaplan K.B., Swedlow J.R., Morgan D.O., Varmus H.E. c-Src enhances the spreading of Src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 9:1995;1505-1517.
22. Klohs W.D., Fry D.W., Kraker A.J. Inhibitors of tyrosine kinase. Curr Opin Oncol. 9:1997;562-568.
23. Kronenberg H.M. Parathyroid hormone Mechanism of action . Favus M.J. Primer on the metabolic bone diseases and disorders of mineral metabolism, 3rd ed. 1996;68-70 Lippincott-Raven, Philadelphia, PA.
24. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA. 90:1992;4485-4489.
25. Lowell C.A., Niwa M., Soriano P., Varmus H.E. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood. 87:1996;1780-1792.
26. Luttrell D.K., Luttrell L.M., Parsons S.J. Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src. Mol Cell Biol. 8:1988;497-501.
27. Lydon N.B., Gay B., Mett H., Murray B., Liebetanz J., Gutzwiller A., Piwnica-Worms H., Roberts T.M., McGlynn E. Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. Biochem J. 287:1992;985-993.
28. Maa M.C., Wilson L.K., Moyers J.S., Vines R.R., Parsons J.T., Parsons S.J. Identification and characterization of a cytoskeleton-associated, epidermal growth factor sensitive pp60c-src substrate. Oncogene. 7:1992;2429-2438.
29. Missbach, M. Preparation of 4-aminopyrrolo[2,3-d]pyrimidines as inhibitors of the protein tyrosine kinase pp60c-src. WO 9610028, Ciba-Geigy AG, Switzerland; 1996.
30. Mohammadi M., Schlessinger J., Hubbard S.R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 86:1996;577-587.
31. Mundy G.R. Bone remodeling and its disorders. 1995;50-53 Martin Dunitz Ltd, London, UK.
32. Nakamura I., Sasaki T., Tanaka S., Takahashi N., Jimi E., Kurokawa T., Kita Y., Ihara S., Suda T., Fukui Y. Phosphatidylinositol-3 kinase is involved in ruffled border formation in osteoclasts. J Cell Physiol. 172:1997;230-239.
33. Neet K., Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells. 1:1996;147-169.
34. Panek R.L., Lu G.H., Klutchko S.R., Batley B.L., Dahring T.K., Hamby J.M., Hallak H., Doherty A.M., Keiser J.A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 283:1997;1433-1444.
35. Parfitt A.M., Mathews C.H.E., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationship between surface, volume, and thickness of iliac trabecular bone in aging and osteoporosis. J Clin Invest. 72:1983;1396-1409.
36. Parsons J.T. Integrin-mediated signalling Regulation by protein tyrosine kinases and small GTP-binding proteins . Curr Opin Cell Biol. 8:1996;146-152.
37. Parsons J.T., Parsons S.J. Src family protein tyrosine kinases Cooperating with growth factor and adhesion signaling pathways . Curr Opin Cell Biol. 9:1997;187-192.
38. Piwnica-Worms H., Saunders K.B., Roberts T.M., Smith A.E., Cheng S.H. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell. 49:1987;75-82.
39. Rodan G.A., Raisz L.G., Bilezikian J.P. Pathophysiology of osteoporosis. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of bone biology. 1996;979-990 Academic Press, San Diego, CA.
40. Roodman G.D. Advances in bone biology The osteoclast . Endocrin Rev. 17:1996;308-332.
41. Rüeggsegger P., Koller B., Müller R. A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int. 58:1996;24-29.
42. Sabatini M., Boyce B., Aufdemorte T., Bonewald L., Mundy R.G. Infusions of recombinant human interleukin 1α and 1β cause hypercalcemia in normal mice. Proc Natl Acad Sci USA. 85:1988;5235-5239.
43. Schwartzberg P.L., Xing L., Hoffmann O., Lowell C.A., Garrett L., Boyce B.F., Varmus H.E. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev. 11:1997;2835-2844.
44. Serban D., Rordorf-Adam C. Quantitation of serum amyloid P component by an enzyme-linked immunoassay. J Immunol Methods. 90:1986;159-164.
45. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
46. Songyang Z., Carraway K.L. III, Eck M., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C., Lorenzo M.J., Ponder B.A.J., Mayer B.J., Cantley L.C. Catalytic specificity of protein-tyrosine kinases is critical for selective signaling. Nature. 373:1995;536-539.
47. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 64:1991;693-702.
48. Stein P.L., Vogel H., Soriano P. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 8:1994;1999-2007.
49. Susa M., Standke G.J., Jeschke M., Rohner D. Fluoroaluminate induces pertussis toxin-sensitive protein phosphorylation differences in MC3T3-E1 osteoblastic and NIH3T3 fibroblastic cells . Biochem Biophys Res Commun. 235:1997;680-684.
50. Tanaka S.N., Takahashi N., Udagawa T., Murakami H., Nakamura I., Kurokawa T., Suda T. Possible involvement of focal adhesion kinase, p125Fak, in osteoclastic bone resorption. J Cell Biochem. 58:1995;424-435.
51. c-src, preferentially on ruffled border membrane. FEBS Lett. 313:1992;85-89.
52. Tanaka S., Amling M., Neff L., Peyman A., Uhlmann E., Levy J.B., Baron R. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature. 383:1996;528-531.
53. Teti A., Taranta A., Migliaccio S., Degiorgi A., Santandrea E., Villanova I., Faraggiana T., Chellaiah M., Hruska K.A. Colony stimulating factor-1-induced osteoclast spreading depends on substrate and requires the vitronectin receptor and the c-src proto-oncogene. J Bone Miner Res. 13:1998;50-58.
54. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:1997;513-609.
55. Thomas S.M., Soriano P., Imamoto A. Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature. 376:1995;267-271.
56. Uy H.L., Dallas M., Calland J.W., Boyce B.F., Mundy G.R., Roodman G.D. Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage. J Bone Miner Res. 10:1995;295-301.
57. Xu W., Harrison S.C., Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:1997;595-602.
58. Yamaguchi H., Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 384:1996;484-489.
59. c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. J Clin Invest. 91:1993;2791-2795.